Mutation update: the spectra of nebulin variants and associated myopathies

Vilma-Lotta Lehtokari,^{1*} Kirsi Kiiski,¹ Sarah A. Sandaradura,^{2,3} Jocelyn Laporte,⁴ Pauliina Repo,¹ Jennifer A. Frey,⁵ Kati Donner,⁶ Minttu Marttila,¹ Carol Saunders,⁷ Peter G. Barth,⁸ Johan T. den Dunnen,⁹ Alan Beggs,¹⁰ Nigel F. Clarke,^{2,3} Kathryn N. North,¹¹ Nigel G. Laing,¹² Norma B. Romero,¹³ Thomas L. Winder,⁵ Katarina Pelin,¹⁴ and Carina Wallgren-Pettersson¹

¹ The Folkhälsan Institute of Genetics and the Department of Medical Genetics, Haartman Institute, University of Helsinki, Helsinki, Finland; ² INMR, The Children's Hospital at Westmead and Sydney Medical School, University of Sydney, Sydney, Australia; ³ Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, Australia; ⁴ Department of Translational Medicine, IGBMC, Inserm U964, CNRS UMR7104, Collège de France, Strasbourg University, Illkirch, France; ⁵ Prevention Genetics Marshfield, Wisconsin, USA; ⁶ Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland; ⁷ Center for Pediatric Genomic Medicine Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA; ⁸ Department of Pediatric Neurology, Emma Children's Hospital/AMC, University of Amsterdam, Amsterdam, The Netherlands; ⁹ Human and Clinical Genetics,

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/humu.22693.

Leiden University Medical Center, Leiden, The Netherlands; ¹⁰ Division of Genetics and Genomics, Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School, USA; ¹¹ Murdoch Childrens Research, Melbourne, Australia; ¹² Centre for Medical Research University of Western Australia and Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, Perth, Australia; ¹³ Myology Institute, UPMC Paris-6, INSERM UMR 974, GHU La Pitié-Salpêtrière, Paris, France; ¹⁴ Department of Biosciences, Division of Genetics, University of Helsinki, Helsinki, Finland

***Correspondence to:** Vilma-Lotta Lehtokari, PhD, The Folkhälsan Institute of Genetics and the Department of Medical Genetics, Haartman Institute, University of Helsinki, Biomedicum Helsinki, PO Box 63 (Haartmaninkatu 8), 00014 University of Helsinki, Finland. E-mail: vilma.lehtokari@helsinki.fi

Grant Sponsor

This work was supported by the Association Française contre les Myopathies, the Sigrid Jusélius Foundation, the Academy of Finland, the Finska Läkaresällskapet and the Medicinska understödsföreningen Liv och Hälsa r.f. (to V.-L.L., M.M., K.P. and C.W.P.) CWP is a member of the TREAT-NMD Alliance. Work in the Beggs laboratory was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the NIH grant R01 AR044345 and by the Muscular Dystrophy Association (USA) MDA201302. NC was supported by the NHMRC of Australia (APP1035828, APP1026933) and the Foundation for Building Strength for NemaLine Myopathy. NGL was supported by Australian National Health and Medical Research Council (NH&MRC) Fellowship APP1002147 and NH&MRC EU Collaborative Grant APP1055295.

Abstract

A mutation update on the nebulin gene (*NEB*) is necessary because of recent developments in analysis methodology, the identification of increasing numbers and novel types of variants and a widening in the spectrum of clinical and histological phenotypes associated with this gigantic, 183 exons containing gene. Recessive pathogenic variants in *NEB* are the major cause of nemaline myopathy (NM), one of the most common congenital myopathies. Moreover, pathogenic *NEB* variants have been identified in core-rod myopathy and in distal myopathies. In this update, we present the disease-causing variants in *NEB* in 159 families, 143 families with NM and 16 families with NM-related myopathies. Eighty-eight families are presented here for the first time. We summarize 86 previously published and 126 unpublished variants identified in *NEB*. Furthermore, we have analyzed the *NEB* variants deposited in the Exome Variant Server (<http://evs.gs.washington.edu/EVS/>), identifying that pathogenic variants are a minor fraction of all coding variants (~7%). This indicates that nebulin tolerates substantial changes in its amino acid sequence, providing an explanation as to why variants in such a large gene result in relatively rare disorders. Lastly, we discuss the difficulties of drawing reliable genotype-phenotype correlations in *NEB*-associated disease.

Key Words: nebulin, *NEB*, nemaline (rod) myopathy, actin-myosin, sarcomere

Background

The nebulin gene (*NEB*), with its 183 exons, encodes one of the biggest proteins in vertebrates (600 – 900 kDa). This protein is one of the key components of the skeletal muscle sarcomere, where it determines the minimum lengths of the actin filaments and regulates actin-myosin interactions and the calcium sensitivity of force generation (Bang et al., 2006; Chandra et al., 2009; Witt et al., 2006). Nebulin is a highly repetitive protein with the potential to bind more than 200 actin monomers. The major part of nebulin consists of 30 – 35 amino acids long simple repeats, which are arranged into super repeats, each super repeat consisting of seven simple repeats. An actin-binding motif, SDXXYK, is present once in each simple repeat, and a putative tropomyosin-binding motif, WLKGIGW, is present once in each super repeat (Labeit & Kolmerer, 1995). The expression of nebulin is greatest in skeletal muscle, but the protein has also been detected at low abundance in heart and brain (Joo et al., 2004; Kazmierski et al., 2003; Laitila et al., 2012).

All pathogenic variants hitherto known in *NEB* have been recessive, mostly compound heterozygous, and the most common cause of autosomal recessive (AR) nemaline myopathy (NM; MIM# 256030) (Anderson et al., 2004; Kapoor et al., 2013; Lawlor et al., 2011; Lehtokari et al., 2006; Malfatti et al., 2014; Ochala et al., 2011; Pelin et al., 1999; Pelin et al., 2002). Other, less common entities include early-onset distal myopathy without nemaline bodies (Wallgren-Pettersson et al., 2007), a distal form of NM (Lehtokari et al., 2011), core-rod myopathy with generalized muscle weakness (Romero et al., 2009), and a childhood onset distal myopathy with rods and cores (Scoto et al., 2013).

In addition to *NEB* (MIM# 161650), variants in eight different genes are currently known to cause NM; skeletal muscle α -actin (*ACTA1*; MIM#s 102610, 161800), the most frequent cause of sporadic NM, α -slow tropomyosin (*TPM3*; MIM#s 191030, 609284), β -tropomyosin (*TPM2*; MIM#s 190990, 609285), troponin T1 (*TNNT1*; MIM#s 191041, 605355), cofilin-2 (*CFL2*; MIM#s 601443, 610687), Kelch repeat and BTB/POZ domains-containing protein 13 (*KBTD13*; MIM#s 613727, 609273), Kelch-like family member 40 (*KLHL40*; MIM#s 615340, 615384, also known as Kelch repeat and BTB/POZ domains-containing protein 5, *KBTD5*) and Kelch-like family member 41 (*KLHL41*; MIM#s 607701, 615731, also known as Kelch repeat and BTB/POZ domains-containing protein 10, *KBTD10*) (Pelin et al., 1999; Nowak et al., 1999; Laing et al., 1995; Donner et al., 2002; Johnston et al., 2000; Agrawal et al., 2007; Sambuughin et al., 2010; Ravenscroft et al., 2013; Gupta et al., 2013, respectively).

The nebulin gene and the reference sequences

The gene encoding nebulin covers 249 kb in the chromosomal region 2q23 and has 183 exons. Translation initiates in exon 3 and continues to the last exon. A repetitive region in the middle of the nebulin gene complicates analytical testing. The triplicated region (TRI) of 24 exons is arranged as three sets of eight nearly perfectly repetitive exons (82-89, 90-97, and 98-105). Among each set of repetitive exons there are too few unique nucleotides to differentiate one copy from the other two using most analysis methods; for example, differentiating exon 82 from 90 or 98. By convention, therefore, a novel variant identified in “exon” 82-90-98 is described as if it were located in exon 82, and not 90 or 98. The triplicated region is also thought to undergo alternative splicing, but firm experimental evidence of this is still lacking.

Alternatively spliced exons include exons 63-66, 143-144 and 167-177. The exons 63-66 seem to be expressed together, being either present or absent from the transcript. The expression of the exon pair 143 and 144 is mutually exclusive, while exons 167-177 are independently spliced (Donner et al., 2004; Laitila et al., 2012; Pelin and Wallgren-Pettersson, 2008). It has been hypothesized that such a large variety of different nebulin isoforms is needed because of the diverse requirements on muscle tissue at different stages of development, in various muscle fiber types and in different muscles (Kazmierski et al., 2003; Labeit et al., 2011; Laitila et al., 2012; McElhinny et al., 2003).

We have updated the location of all *NEB* exons in the genomic reference sequence NG_009382.1, and deposited two *NEB* mRNA reference sequences, NM_001164507 (transcript variant 1) and NM_001164508 (transcript variant 2) into GenBank at NCBI (<http://www.ncbi.nlm.nih.gov/>). The transcript Variant 1 sequence includes the alternative exon 143, and the transcript Variant 2 sequence the alternative exon 144. To simplify the description of variants, although data suggest exons 143 and 144 are never expressed in the same transcript, we use NM_001271208.1 as a reference covering 26307 bp (coding region 25683 bp) including both exons 143 and 144.

Nebulin variants and the LOVDdatabase

To date, we have ascertained 212 (126 novel and 86 published) different pathogenic variants in *NEB* in 159 families in which both pathogenic variants have been identified using a variety of different analysis methods: Single-Strand Conformation Polymorphism, denaturing High Performance Liquid Chromatography, Sanger sequencing of genomic or cDNA, next-generation sequencing of *NEB* alone or of whole exomes, our self-designed microarray for

detecting copy number variants (NM-CGH), and targeted next-generation sequencing of a panel of known neuromuscular genes, including all known NM genes. The identified variants are dispersed all along *NEB*.

In the majority (83%) of families, the patients are compound heterozygous for two different variants. Twelve variants have only been seen in homozygous form and nine variants in both heterozygous and homozygous forms.

The most common types of variants are splice site mutations (34%), followed by frameshift mutations (32%) caused by small (<20 bp) deletions or insertions, nonsense mutations (23%), and missense mutations (7%). Large deletions and duplications (>1kb) are rare (4%) (Figure 1).

In our study, only those missense variants that are predicted to affect nebulin-actin or nebulin-tropomyosin interactions have been interpreted as pathogenic. It is likely that some missense sequence variants outside these regions are also disease-causing, but it is very difficult to distinguish these variants from rare polymorphisms that occur in NM patients by chance. Therefore, we have adopted a conservative approach categorizing missense changes to minimize the chance of misinterpreting rare benign variants as being pathogenic. Both nonsense and frameshift variants are predicted to lead to truncation and/or degradation of the isoform where the mutated exon is expressed.

In the current paper, all identified variants, both previously published and novel, have been mapped according to the coding sequence of NCBI GenBank cDNA reference sequence NM_001271208.1. All variants have been deposited in the LOVD-powered *NEB* variant database (<http://NEB.LOVD.nl>).

The spectrum of myopathies caused by variants in *NEB*

Most commonly, variants in *NEB* have been associated with NM. Out of 159 families included in this article, 143 (90%) have NM, while only 16 families with variants in *NEB* have other disorders (Figure 2); early-onset distal myopathy without nemaline bodies (4 families), a distal form of NM (3 families), core-rod myopathy with generalized muscle weakness (3 families), and a childhood onset distal myopathy with rods and cores (3 families). In addition, we report three families with fetal akinesia/lethal multiple pterygium syndrome.

Nemaline myopathy

NM was described by two separate groups in 1963 as a novel disease entity (Conen et al., 1963; Shy et al., 1963). The most common clinical presentation is early-onset muscle weakness predominantly affecting proximal limb muscles. The hallmark feature on muscle pathology is the accumulation of Z-disk and thin filament proteins into aggregates named nemaline bodies or rods, usually accompanied by disorganization of the muscle Z-disks (Conen et al., 1963; Magee and Shy, 1956; Shy et al., 1963; Wallgren-Pettersson et al. 1995). However, NM varies in clinical severity. Six clinical subgroups are used to classify the disorder: the severe, intermediate, and typical congenital forms of NM, a mild childhood/juvenile onset form; adult-onset NM; and other (atypical) forms of NM (Table 1) (Wallgren-Pettersson and Laing, 2000). Clinical classification of the disorder in individual

patients may be difficult early in life, as progression during childhood is one of the features distinguishing between categories. Also, patients sharing the same variants may have different disease severities, even within the same family (Lehtokari et al., 2006).

The variants identified in the 143 NM families are summarized in Supp. Table S1A-F. Patients from 24 families had severe congenital NM, patients from 15 families had the intermediate congenital form, 51 patients had the typical congenital form (individual sibs from four families had either the typical or the intermediate forms of NM), and 7 had mild childhood-onset NM. None had adult-onset NM, while 18 were classified into the group of “other forms”, and 32 had an unspecified form of NM, i.e., clinical data were lacking (Figure 2). In 50 NM families, both pathogenic variants had been published previously, while in 12 families, only one of two compound heterozygous variants had been published. Eighty-one nebulin-related NM families with both pathogenic variants identified are presented here for the first time.

Distal nebulin myopathy without nemaline rods

Variants in *NEB* were long believed only to cause NM. However, in 2007, we discovered two different homozygous *NEB* missense variants, causing a novel disease entity in four Finnish families with a clinically mild distal myopathy (Wallgren-Pettersson et al., 2007). The patients presented with only distal weakness, in a pattern similar to that of Laing myopathy (Lamont et al., 2014), and no nemaline bodies were apparent at light microscopy. In one of the patients, no rods were found in any of the four biopsies taken over the years of diagnostic workup (at ages of 14, 16, 27 and 29 years). Both variants were present in homozygous form in two Finnish families each, in five and two individuals, respectively (Table 2A) (Wallgren-Pettersson et al., 2007). When present in a compound heterozygous state with more disruptive

variants, the same variants are known to cause NM. One of the missense variants, p.Ser6366Ile, resides in *NEB* exon 122 and causes increased nebulin-actin affinity, while the second missense variant, p.Thr7382Pro in *NEB* exon 151 reduces the affinity of nebulin for tropomyosin (Marttila et al., 2014). The differences in muscle involvement in NM and distal nebulin myopathy, as well as the milder phenotype are intriguing. A possible explanation could be that the missense variants in *NEB*, being less disruptive, would cause milder, distal-only myopathy without nemaline rods.

Distal nemaline myopathy

A few years after the identification of the above group of patients, we identified *NEB* variants in three non-Finnish patients in two unrelated families, presenting in childhood with distal weakness and showing nemaline bodies in their first, diagnostic biopsy (F227 and F343, Table 2B) (Lehtokari et al., 2011). Here we report one more patient with a distal form of NM. This Finnish patient (F156, Table 2B) is compound heterozygous for an exon 122 missense variant (p.Ser6366Ile) and a splice site variant in intron 53 (c.7228-1G>T). We can thus confirm that NM and distal myopathies caused by *NEB* variants form a clinical and histological continuum, and that NM should be considered as a differential diagnosis in patients presenting with an early-onset, predominantly distal myopathy.

Core-rod myopathy

We previously published *NEB* variants underlying a severe form of core-rod myopathy in one patient (F220, Table 2C) (Romero et al., 2009). Here we report two additional families, F400 and F378, with clinically mild and severe forms, respectively, in which the patients have core structures in their biopsies in addition to nemaline rods. Both the father and the three affected children of the consanguineous family F400 are affected and homozygous for a recessive

variant in the donor splice site of exon 25 (c.2415+1G>A, Table 2C), resulting in a pseudodominant pattern of inheritance. In this family, the distribution of muscle weakness was unusual in that the patients had normal strength in the leg muscles. So far, to our knowledge, no other patients with the histological picture of core-rod myopathy and upper limb-only proximal muscle weakness have been found to have variants in *NEB*.

Distal core-rod myopathy

Recently, Scoto and co-workers reported a childhood-onset distal myopathy with rods and cores, caused by compound heterozygous *NEB* variants (the Ashkenazi founder deletion of exon 55 and a frameshift mutation in the alternatively spliced exon 172, family CR2, Table 2D) (Scoto et al., 2013). In the current paper, we report compound heterozygous *NEB* variants identified in two French families in which the patients had a similar distal phenotype (F282, F410, Table 2D). Interestingly, the patients in family F282 share a frameshift variant in exon 171 with the core-rod myopathy patient of F220 and F127 with severe NM. The patients of family F282 had a distal distribution of limb muscle weakness, combined in one of them with neck flexor and respiratory muscle weakness. The histological pattern was a combination of definite rods and cores. One of the patients, like the one presented in the paper by Scoto and co-workers, has required nocturnal noninvasive ventilatory support. Both patients are ambulant, at the ages of 11 and 15 years, respectively.

Fetal akinesia

We have identified *NEB* variants with fetal akinesia/lethal multiple pterygium syndrome (D12-060 and F412), and fetal akinesia, respectively (F384) (Table 2E). The muscle biopsy performed on the fetuses from F412 showed almost complete replacement of muscle with adipose tissue.

Genotype-phenotype correlations in patients with *NEB* variants

Although the number of *NEB* variants identified is now substantial, it is not adequate for statistical analyses. We were not able to obtain statistically significant genotype-phenotype correlations in terms of the type of variant in relation to the clinical classification of the patient's disease. It is to be noted that the same variant can be associated with different forms of NM, and even with different myopathies.

We examined the variants, their locations, and the phenotypes they cause from different angles. Variants in alternatively spliced exons might be hypothesized to help us understand the function of the different exons and isoforms in different muscles or muscle fibers. However, the variants are most commonly heterozygous, and combined with a variant in an exon expressed in all isoforms. Also, the variants in alternatively spliced exons are still rather small in number, making it impossible at this time to draw conclusions about the functions of different exons based on the variants identified in patients. Variants in exons 63-66 and 143-144 may, in the future, shed light on the function of these exons.

One approach towards finding genotype-phenotype correlations was to compare the 48 families with pathogenic variants in the alternatively spliced exons; 35 families had one, and 13 families both variants residing in the alternatively spliced exons 63-66, 143-144, or 167-177 (ALT1, ALT2 and ALT3, respectively in Tables 2-4 and Supp. Table S1). Of these, patients in two families had severe presentations, patients in three families had intermediate congenital NM, 11 had typical congenital NM, and 15 had an unspecified form of NM (Supp. Table S1). Interestingly, we noticed that many of these patients (14 families) presented exceptional clinical and/or histological features. Furthermore, three showed unusual

histological features; one had core-rod (F220) and two distal core-rod myopathy (CR2 and F410, Table 2).

Two families with patients assigned to the group of “other forms of NM” had variants in the triplicate region (TRI) of *NEB*. One Finnish patient (F316) belonging to the group of “other forms of NM” was compound heterozygous for variants in non-alternatively spliced exons (exons 68 and 122), and another (non-Finnish) patient (F309) was compound heterozygous for a nonsense variant in exon 78 and a very unusual large duplication (>103 kb altogether), with one breakpoint upstream of *NEB* and the other breakpoint in intron 51 (Supp. Table S1E).

In addition to the Ashkenazi Jewish founder mutation (exon 55 deletion), we have identified seven other large deletions or duplications (1 – 133 kb) in nine families. The clinical severity varied in these patients from severe congenital NM (F181) through typical congenital NM (F45 and F318) to mild clinical phenotypes (F309). One patient had core-rod myopathy (F410). Two families, F211 with typical, and F333 with mild NM, shared a deletion of exons 43-45, and two families shared a deletion of exon 77, but had unspecified forms of NM (PG-F19 and PG-F20).

Variants in the alternatively splice exons 63-66

Patients in seven families had variants in the alternatively spliced exons 63-66. Patients from families F270, F284, and F386 were classified as having “other forms” of NM (Supp. Table S1E). They all had pronounced weakness of axial muscles, with relative sparing of limb muscles, as opposed to the usual distribution of axial, proximal limb muscle, and later distal involvement. Patients from family F4 had the typical congenital (Supp. Table S1C) and

Bos227-1 the severe congenital form of NM (Supp. Table S1A). No tissue samples were available from a fetus from family F384, where the pregnancy was terminated because of fetal akinesia, (Table 2E). One patient (PG-F5), with a splice site variant in intron 66, had an unspecified form of NM (Supp. Table S1F).

These data suggest that exons 63-66 are always expressed together, i.e. all four exons are either present in the transcript producing the isoform, or are absent from it, and they encode one super-repeat highly homologous to super-repeat 11 (Donner et al., 2004). Biopsies from eight different skeletal muscles analyzed by reverse transcription PCR in the study of Laitila and colleagues expressed both types of transcripts, i.e. those including and those excluding exons 63-66 (Laitila et al., 2012). Furthermore, no significant differences in expression levels of exons 63-66 were observed in an expression microarray analysis of 21 different types of leg muscles (Laitila et al., 2012). These results indicate that both transcripts expressing exons 63-66 and transcripts lacking exons 63-66 are needed for normal muscle function in many different types of muscles. All patients with truncating variants in exons 63-66 are expected to preferentially express nebulin isoforms lacking these exons.

Variants in exons 143-144

Altogether three families had variants in exons 143 or 144, which are alternatively spliced. An adult sibling pair with a heterozygous nonsense mutation of the alternatively spliced exon 143 had ophthalmoplegia, which is very unusual in NM (F187, Supp. Table S1E). In this family, and in the family with a homozygous nonsense mutation of the alternative exon 144 (F390, Supp. Table S1E), one of the sibs had undergone anesthesia and had had difficulty waking up from it, although the situation did not progress to overt malignant hyperthermia. Again, this is an unusual phenomenon in NM (Cunliffe and Burrows, 1985; Shenkman et al.,

2000; Stackhouse et al., 1994). Other unusual features in F390 with a truncating mutation in exon 144 were that the biopsy showed dystrophic features, and that the neck flexors, which are almost always weak in NM, had normal muscle strength. Additionally the patient of family F114, with an unspecified form of NM, had a heterozygous frameshift mutation in exon 144 (Supp. Table S1F). We have no clinical or histological data on this family.

It seems that exons 143 and 144 are never expressed together in the same isoform, but both types of transcripts are usually present at different expression levels in the same muscle (Donner et al., 2006; Laitila et al., 2012). The patients with truncating mutations in exon 144 are expected only to express nebulin exon 143 isoforms, whereas patients with the truncating mutation in exon 143 are expected only to express exon 144 isoforms. The protein domains encoded by exons 143 and 144 differ in charge and hydrophobicity, and they appear to have different and important regulatory functions in developing muscles (Donner et al., 2004; Donner et al., 2006).

Variants in exons 167-177

Patients from 38 families had variants in the alternatively spliced exons 167-177: Patients from one family (F407) had severe, three families had intermediate (G22593, G36659 and P8), and ten families had typical NM (SYD-F1, SYD-F2, SYD-F3, F328, AG-F1, F318, F340, F349, G19106, F238).

Nine families with variants in the alternatively spliced exons 167-177 had been assigned to the category “other forms” of NM: patients from three families had fasciculations (F127, F206, F382), and three a selective pattern of muscle weakness different from that of the typical form of NM (F189, F389, F324). Two other families (F79 and F81) with different

homozygous frameshift variants in the same exon (171) had NM with rigid neck and/or spine. One patient (F31) had a very severe, unusual form of NM and was born with hypospadias and micropenis (Supp. Table S1E).

Patients from one family had severe core-rod myopathy (F220) and two a distal form of core-rod myopathy (F282 and CR2). Families F220 and F282 share a frameshift mutation in exon 171 (p.Glu8098fs) (Table 2C and 2D). The same variation was also identified in the cousin of the patient in F282 who had a severe, unusual form of NM with fasciculations (F127, Supp. Table S1E).

No clinical details are available of patients in 14 of the families with variants in exons 167-177 (Supp. Table S1F).

Exons 167-177 are spliced independently of each other, and all encode 31 amino acid long simple repeats of the Z-disk region of nebulin (Donner et al., 2004). The beginning of this region binds desmin at the edge of the Z-disk, and the simple repeats extending into the Z-disk are thought to specify Z-disk width in different fiber types (Bang et al., 2002; Tonino et al., 2010). The variants are expected to reduce nebulin isoform diversity, and may affect nebulin-desmin interactions as well as Z-disk assembly.

Of the 67 different frameshift mutations identified in *NEB* to date, 29 reside in alternatively spliced exons, and 27 of them in exons 167-177. All variants identified in exons 167-177 are truncating (frameshift or nonsense). Notably, only one patient (F88, severe NM, Supp. Table S1A), had a homozygous frameshift variant in an exon that is not alternatively spliced

(c.25200del in exon 180), suggesting that homozygous frameshift variants are not tolerated in ubiquitously expressed exons, unless at the very 3' end of the gene.

Shared, recurrent and founder mutations in *NEB*

There is only one relatively common founder mutation known in *NEB*, with world-wide occurrence, i.e. the 2.5 kb deletion of the entire exon 55 (p.Arg2478_Asp2512del) identified in the Ashkenazi Jewish population (Anderson et al., 2004). The carrier frequency of this variant in the Ashkenazi Jewish population is 1:108-168 (Anderson et al., 2004; Lehtokari et al., 2009; Scott et al., 2010). In our cohort, this variant was identified in 13 families (in homozygous form in four and in heterozygous form in nine families).

Three different variants identified in Finnish families may be regarded as founder mutations in the Finnish population; (p.Ser6366Ile in ex122, p.Thr7382Pro in ex151, and p.Thr6350Profs*4 in ex122). The missense variants were both present in homozygous form in two distal nebulin myopathy families each. The exon 122 missense variant was identified in heterozygous form in eight NM families, including one with distal NM, and in homozygous form in two families with distal nebulin myopathy. The exon 151 missense variant was found in heterozygous form in three NM families and in homozygous form in two families with distal nebulin myopathy. The carrier frequencies of these two variants in Finland were estimated based on the Sequencing Initiative Suomi (SISU) project data (<http://www.sisuproject.fi/>). According to SISU, the carrier frequency of the p.Ser6366Ile variant is 1:653, and of the p.Thr738Pro 1:1108 in the Finnish population. The third Finnish founder mutation, a frameshift variant, was identified in two NM families. One of the Finnish families, F1 shows compound heterozygosity for the p.Thr7382Pro and the p.Thr6350Profs*4 variants (Supp. Table S1C) (Lehtokari et al., 2006; Wallgren-Pettersson et al., 2007).

In addition to the four founder mutations, 28 different variants were shared between two or more families, and 11 different variants between three or more families. Our haplotype results show that the shared variants in ten families occur on different haplotypes, indicating that these variants have arisen *de novo* more than once in humans, while in 15 families the haplotype is shared (Table 3).

Only one location in *NEB* can be considered to be a true mutational hotspot; Nucleotide c.3255+1 (donor splice site of intron 32) was mutated in 15 unrelated families, and c.3255+2 in two unrelated families. Recurrent mutations were also detected in the donor splice site of intron 36. Three families showed c.3987+1G>A, and two families c.3987+1_3987+2inv (Table 3). There is no obvious explanation, e.g. any repetitive sequence, why these nucleotides seem to be mutated recurrently.

A nonsense variant in exon 119 (p.Gln6226*) was identified in four families. In two families the patients are cousins (F127 with severe other form of NM, Supp. Table S1E, and F378 with severe NM with cores, Table 2). In our data set there are currently only two families sharing the same two compound heterozygous variants. Families F349 and G19106 share a nonsense variant in exon 119 (p.Gln6226*) and also a splice site variant c.24684G>A in exon 175 (Supp. Table S1C). Another pair of families sharing the same variants is F17 and F267 (c.3987+1G>A and c.20845dup, Supp. Table S1B and F). F17 was sent from U.S. and F267 is from the Netherlands. These families share the haplotype (markers D2S2277, D2S2275 and D2S2299 used). No haplotype data was available for the families F349 (from Switzerland) and G19106 (from France).

***NEB* variants in healthy individuals and disease incidence estimates**

The Exome Variant Server (<http://evs.gs.washington.edu/EVS/>), a collection of exome-sequencing data of 6,503 DNA samples from unrelated individuals of African American and European American origin, contains 1,295 variants in *NEB* (ESP6500 data release, February 2014). To the best of our knowledge, the EVS cohorts do not include individuals with neuromuscular disorders. Of the 1295 variants, 522 represent missense changes, 488 variants are within introns (excluding splice sites), 262 are synonymous changes in the coding region, ten frameshift mutations, six in-frame deletions or insertions, three intronic splice site mutations, and two nonsense mutations. The in-frame deletions and insertions affect 1-5 amino acids each, and we consider them as being non-pathogenic due to their high occurrence rate in the study population, with several homozygotes identified. Some of the indels may also represent sequencing or annotation errors. Of the synonymous changes, two are part of 5'splice signals and may affect splicing. Of the 522 missense variants, 31 reside in conserved actin-binding sites of nebulin and could be considered to affect actin binding, while seven are in putative tropomyosin-binding sites and may affect nebulin-tropomyosin interaction. Of the approximately 6,000 individuals whose samples were successfully exome sequenced, 69 were heterozygous carriers of pathogenic *NEB* variants, which equals a carrier frequency of approximately 1/87, and a disease incidence of approximately 1 in 30,000 for recessively inherited myopathies caused by *NEB* variants. The incidence of NM in one population has previously been estimated as 0.02 per 1,000 live births (1 in 50,000) (Wallgren-Pettersson, 1990).

Clinical and diagnostic relevance

Variants in *NEB* may cause NM with a wide range of clinical severities as well as other related entities. If the other known NM genes have been ruled out as the cause of the disease in a patient with NM, the next step in the diagnostic procedure would be to analyze the patient for *NEB* variants. Most often *NEB* variants are associated with the typical form of recessive NM, in which the clinical picture consists of myopathic facies, nasal voice or even dysarthria, pronounced neck flexor, axial muscle and limb girdle weakness in comparison with the less affected, but weak proximal limb muscles. Distal muscle involvement, including foot drop, is often noted later. Respiratory involvement is often out of proportion to the weakness of the other muscles (Lehtokari et al., 2006; Wallgren-Pettersson, 1989).

In some cases, histological findings may help direct mutation detection. Nebulin positivity is the rule, but if the muscle biopsy shows uneven staining for nebulin, a nebulin variant appears more likely than an *ACTA1* variant (Gurgel-Giannetti et al., 2001; Pelin et al., 1999; Sewry et al., 2001). If there are intranuclear nemaline bodies, an excess of thin filaments, retained expression of cardiac actin in muscle, or zebra bodies, an *ACTA1* variant is likely (Nowak et al., 1999; Nowak et al., 2007).

Molecular verification of the diagnosis is a prerequisite for determining the mode of inheritance, for accurate genetic counseling and, where desired, for enabling prenatal diagnosis in future pregnancies. The carrier frequency of the exon 55 deletion in the Ashkenazi Jewish population may be as high as 1:110, so after exclusion of the smaller genes as the causative gene in the family, this variant would be a first choice in further molecular diagnostic analysis of patients in many parts of the world. In Finnish patients, the Finnish

founder mutations can be sought for first. Attention should also be paid to the donor splice sites of intron 32 and intron 36, which are frequently mutated.

It has become evident that, even considering the now large number of patients with clarified genotypes, it is extremely difficult to discern any detailed genotype-phenotype correlations in *NEB*-caused NM. This renders variant types unreliable as a basis for determining the prognosis in individual patients. Missense variants, however, do not seem to be commonly pathogenic, and in order to underlie NM, it is likely that a missense variant needs to be combined with a more disruptive variant.

Relevant animal models

Four nebulin mouse models have been published; two *Neb* knock-out models with very severe phenotypes (Bang et al., 2006, Witt et al., 2006), one homozygous for the deletion of exon 55 (Ashkenazi founder mutation) also with a very severe phenotype (Ottenheijm et al 2013) and a recent one with a deletion of the SH3-domain of nebulin, with no structural or histological skeletal muscle abnormalities, but slight impact on muscle function (Yamamoto et al., 2013). Furthermore, a zebrafish model homozygous for a splice site mutation in *neb* also shows a severe phenotype (Telfer et al., 2012).

Conclusions and future prospects

With next-generation sequencing (NGS) techniques becoming more common in the diagnostic field, it is important to bear in mind that no technique alone reveals all variants in the gigantic *NEB* gene. There are regions of great homology that cause difficulties in sequencing, such as the *NEB* triplicate region consisting of exons 82-89, 90-97, 98-105. Copy number variants spanning the entire *NEB* triplicate region block have, however, been

identified with our NM-CGH microarray (Kiiski et al., 2013). Small variants in this region can be unraveled through whole-genome sequencing and subsequent Sanger sequencing. Studies of the triplicate region are ongoing to shed light on the relevance of this region for normal and altered gene function.

Missense changes and small in-frame deletions and insertions in *NEB* should be verified using functional analyses in order to determine the consequence of the change in the protein.

Variants affecting highly conserved regions of nebulin, such as those altering actin-binding sites, may be regarded as pathogenic.

The clinical and histological spectrum of entities caused by variants in *NEB* is a continuum, ranging in severity from the severe form with perinatal onset to the mild forms. The distribution of weakness can vary from generalized muscle weakness, more pronounced in proximal limb muscles, to distal-only involvement, although neck flexor weakness appears to be rather consistent. Histological patterns range from a severe, but almost invariably non-dystrophic disturbance of the myofibrillar pattern to an almost normal picture on hematoxylin-eosin staining, with or without nemaline bodies, sometimes combined with cores.

Genotype-phenotype correlations remain mostly vague. Although variants in *NEB* have been unambiguously shown to be a common cause of recessive NM, these variants may not be the only factors determining the severity of the disease. Modifying genetic factors are currently being revealed by the use of new techniques such as whole-exome and whole-genome sequencing. In addition, other determinants including good clinical care, nutrition and other factors influence the well-being of the patients.

Ethical approval

The study has been approved by the Ethics Committee of the Children's Hospital, University of Helsinki, Helsinki, Finland.

Acknowledgments

We thank the following clinicians/colleagues for providing data and /or DNA samples on one or two patients each: Drs C. Angelini, N. Barisic, N. Belart, J. Bohm, L. Brueton, K. Bushby, C. Dias, A. Echaniz-Laguna, A. Forjaz de Sampaio, M. Garcia-Barcina, C. Gardiner, H. Gervais-Bernard, C. Graziano, J. Greenberg, S. Iannaccone, L. Jarre, P.-Y. Jeannet, P.S. Jouk, F. Juul-Hansen, T. Homfray, E. Honey, I. Hughes, R. Khajuria, C. Kubisch, S. Kapoor, T. Löppönen, L. Mehta, J. Monteiro, V. Lacroze, H. Lochmüller, S. Pajusalu, S. Penttilä, B. Porfirio, H. Roper, S. Rudnik-Schöneborn, N. Safina, U. Schaeffer, T. Stojkovic, K. Swoboda, H. Topaloglu, C. Vial, M. de Visser, D. Wenger, J. Wilmschurst, H. Yonath, K. Yau, K. Öunap. Dr Luisa Mota-Vieira excluded consanguinity in Family F378, and coordinated the mutation detection efforts relating to this family.

We also thank Vandana Gupta, Emily Todd, Gina Ravenscroft and Bjarne Udd for identifying mutations in one family each. We are grateful to Gunilla Donner and Lotta Eklundh for meticulous secretarial assistance in handling the clinical database.

References

Agrawal PB, Greenleaf RS, Tomczak KK, Lehtokari VL, Wallgren-Pettersson C, Wallefeld W, Laing NG, Darras BT, Maciver SK, Dormitzer PR, Beggs AH. 2007. Nemaline myopathy with minicores caused by mutation of the CFL2 gene encoding the skeletal muscle actin-binding protein, cofilin-2. *Am J Hum Genet* 80:162-167.

Anderson SL, Ekstein J, Donnelly MC, Keefe EM, Toto NR, LeVoci LA, Rubin BY. 2004. Nemaline myopathy in the ashkenazi jewish population is caused by a deletion in the nebulin gene. *Hum Genet* 115:185-190.

Bang ML, Gregorio C, Labeit S. 2002. Molecular dissection of the interaction of desmin with the C-terminal region of nebulin. *J Struct Biol* 137:119-127.

Bang ML, Li X, Littlefield R, Bremner S, Thor A, Knowlton KU, Lieber RL, Chen J. 2006. Nebulin-deficient mice exhibit shorter thin filament lengths and reduced contractile function in skeletal muscle. *J Cell Biol* 173:905-916.

Bohm J, Vasli N, Malfatti E, Le Gras S, Feger C, Jost B, Monnier N, Brocard J, Karasoy H, Gerard M, Walter MC, Reilich P et al. 2013. An integrated diagnosis strategy for congenital myopathies. *PLoS One* 8:e67527.

Chandra M, Mamidi R, Ford S, Hidalgo C, Witt C, Ottenheijm C, Labeit S, Granzier H. 2009. Nebulin alters cross-bridge cycling kinetics and increases thin filament activation: A novel mechanism for increasing tension and reducing tension cost. *J Biol Chem* 284:30889-30896.

Conen PE, Murphy EG, Donohue WL. 1963. Light and electron microscopic studies of "myogranules" in a child with hypotonia and muscle weakness. *Can Med Assoc J* 89:983-986.

Cunliffe M, Burrows FA. 1985. Anaesthetic implications of nemaline rod myopathy. *Can Anaesth Soc J* 32:543-547.

Donner K, Ollikainen M, Ridanpaa M, Christen HJ, Goebel HH, de Visser M, Pelin K, Wallgren-Pettersson C. 2002. Mutations in the beta-tropomyosin (TPM2) gene--a rare cause of nemaline myopathy. *Neuromuscul Disord* 12:151-158.

Donner K, Sandbacka M, Lehtokari VL, Wallgren-Pettersson C, Pelin K. 2004. Complete genomic structure of the human nebulin gene and identification of alternatively spliced transcripts. *Eur J Hum Genet* 12:744-751.

Donner K, Nowak KJ, Aro M, Pelin K, Wallgren-Pettersson C. 2006. Developmental and muscle-type-specific expression of mouse nebulin exons 127 and 128. *Genomics* 88:489-495.

Gajda A, Horvath E, Hortobagyi T, Gergev G, Szabo H, Farkas K, Nagy N, Szell M, Sztriha L. 2013. Nemaline myopathy type 2 (NEM2): Two novel mutations in the nebulin (NEB) gene. *J Child Neurol*.

Gupta VA, Ravenscroft G, Shaheen R, Todd EJ, Swanson LC, Shiina M, Ogata K, Hsu C, Clarke NF, Darras BT, Farrar MA, Hashem A et al. 2013. Identification of KLHL41

mutations implicates BTB-kelch-mediated ubiquitination as an alternate pathway to myofibrillar disruption in nemaline myopathy. *Am J Hum Genet* 93:1108-1117.

Gurgel-Giannetti J, Reed U, Bang ML, Pelin K, Donner K, Marie SK, Carvalho M, Fireman MA, Zanoteli E, Oliveira AS, Zatz M, Wallgren-Pettersson C et al. 2001. Nebulin expression in patients with nemaline myopathy. *Neuromuscul Disord* 11:154-162.

Johnston JJ, Kelley RI, Crawford TO, Morton DH, Agarwala R, Koch T, Schaffer AA, Francomano CA, Biesecker LG. 2000. A novel nemaline myopathy in the amish caused by a mutation in troponin T1. *Am J Hum Genet* 67:814-821.

Joo YM, Lee MA, Lee YM, Kim MS, Kim SY, Jeon EH, Choi JK, Kim WH, Lee HC, Min BI, Kang HS, Kim CR. 2004. Identification of chicken nebulin isoforms of the 31-residue motifs and non-muscle nebulin. *Biochem Biophys Res Commun* 325:1286-1291.

Kapoor S, Singh A, Lehtokari VL, Wallgren-Pettersson C, Batra VV. 2013. Mutations in the nebulin gene in a child with nemaline (rod) myopathy. *Indian J Pediatr* 80:691-693.

Kazmierski ST, Antin PB, Witt CC, Huebner N, McElhinny AS, Labeit S, Gregorio CC. 2003. The complete mouse nebulin gene sequence and the identification of cardiac nebulin. *J Mol Biol* 328:835-846.

Kiiski K, Laari L, Lehtokari VL, Lunkka-Hytonen M, Angelini C, Petty R, Hackman P, Wallgren-Pettersson C, Pelin K. 2013. Targeted array comparative genomic hybridization--a

new diagnostic tool for the detection of large copy number variations in nemaline myopathy-causing genes. *Neuromuscul Disord* 23:56-65.

Labeit S, Kolmerer B. 1995. The complete primary structure of human nebulin and its correlation to muscle structure. *J Mol Biol* 248:308-315.

Labeit S, Ottenheijm CA, Granzier H. 2011. Nebulin, a major player in muscle health and disease. *Faseb j* 25:822-829.

Laing NG, Wilton SD, Akkari PA, Dorosz S, Boundy K, Kneebone C, Blumbergs P, White S, Watkins H, Love DR. 1995. A mutation in the alpha tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy NEM1. *Nat Genet* 10:249.

Laitila J, Hanif M, Paetau A, Hujanen S, Keto J, Somervuo P, Huovinen S, Udd B, Wallgren-Pettersson C, Auvinen P, Hackman P, Pelin K. 2012. Expression of multiple nebulin isoforms in human skeletal muscle and brain. *Muscle Nerve* 46:730-737.

Lamont PJ, Wallefeld W, Hilton-Jones D, Udd B, Argov Z, Barboi AC, Bonneman C, Boycott KM, Bushby K, Connolly AM, Davies N, Beggs AH et al. 2014. Novel mutations widen the phenotypic spectrum of slow Skeletal/beta-cardiac myosin (MYH7) distal myopathy. *Hum Mutat* 37:868-879.

Lawlor MW, Ottenheijm CA, Lehtokari VL, Cho K, Pelin K, Wallgren-Pettersson C, Granzier H, Beggs AH. 2011. Novel mutations in NEB cause abnormal nebulin expression

and markedly impaired muscle force generation in severe nemaline myopathy. *Skelet Muscle* 1:23-5040-1-23.

Lehtokari VL, Pelin K, Sandbacka M, Ranta S, Donner K, Muntoni F, Sewry C, Angelini C, Bushby K, Van den Bergh P, Iannaccone S, Laing NG et al. 2006. Identification of 45 novel mutations in the nebulin gene associated with autosomal recessive nemaline myopathy. *Hum Mutat* 27:946-956.

Lehtokari VL, Greenleaf RS, DeChene ET, Kellinsalmi M, Pelin K, Laing NG, Beggs AH, Wallgren-Pettersson C. 2009. The exon 55 deletion in the nebulin gene--one single founder mutation with world-wide occurrence. *Neuromuscul Disord* 19:179-181.

Lehtokari VL, Pelin K, Herczegfalvi A, Karcagi V, Pouget J, Franques J, Pellissier JF, Figarella-Branger D, von der Hagen M, Huebner A, Schoser B, Lochmuller H et al. 2011. Nemaline myopathy caused by mutations in the nebulin gene may present as a distal myopathy. *Neuromuscul Disord* 21:556-562.

Magee KR, Shy GM. 1956. A new congenital non-progressive myopathy. *Brain* 79:610-621.

Malfatti E, Lehtokari VL, Bohm J, De Winter JM, Schaffer U, Estournet B, Quijano-Roy S, Monges S, Lubieniecki F, Bellance R, Viou MT, Madelaine A et al. 2014. Muscle histopathology in nebulin-related nemaline myopathy: Ultrastructural findings correlated to disease severity and genotype. *Acta Neuropathol Commun* 2:44.

Marttila M, Hanif M, Lemola E, Nowak KJ, Laitila J, Grönholm M, Wallgren-Pettersson C, Pelin K. 2014. Nebulin interactions with actin and tropomyosin are altered by disease-causing mutations. *Skeletal Muscle* 4:15

McElhinny AS, Kazmierski ST, Labeit S, Gregorio CC. 2003. Nebulin: The nebulous, multifunctional giant of striated muscle. *Trends Cardiovasc Med* 13:195-201.

Nowak KJ, Wattanasirichaigoon D, Goebel HH, Wilce M, Pelin K, Donner K, Jacob RL, Hubner C, Oexle K, Anderson JR, Verity CM, North KN et al.. 1999. Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. *Nat Genet* 23:208-212.

Nowak KJ, Sewry CA, Navarro C, Squier W, Reina C, Ricoy JR, Jayawant SS, Childs AM, Dobbie JA, Appleton RE, Mountford RC, Walker KR et al. 2007. Nemaline myopathy caused by absence of alpha-skeletal muscle actin. *Ann Neurol* 61:175-184.

Ochala J, Lehtokari VL, Iwamoto H, Li M, Feng HZ, Jin JP, Yagi N, Wallgren-Pettersson C, Penisson-Besnier I, Larsson L. 2011. Disrupted myosin cross-bridge cycling kinetics triggers muscle weakness in nebulin-related myopathy. *Faseb j* 25:1903-1913.

Ottenheijm CA, Buck D, de Winter JM, Ferrara C, Piroddi N, Tesi C, Jasper JR, Malik FI, Meng H, Stienen GJ, Beggs AH, Labeit S et al. 2013. Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy. *Brain* 136:1718-1731.

Pelin K, Hilpela P, Donner K, Sewry C, Akkari PA, Wilton SD, Wattanasirichaigoon D, Bang ML, Centner T, Hanefeld F, Odent S, Fardeau M et al. 1999. Mutations in the nebulin gene associated with autosomal recessive nemaline myopathy. *Proc Natl Acad Sci U S A* 96:2305-2310.

Pelin K, Donner K, Holmberg M, Jungbluth H, Muntoni F, Wallgren-Pettersson C. 2002. Nebulin mutations in autosomal recessive nemaline myopathy: An update. *Neuromuscul Disord* 12:680-686.

Pelin K, Wallgren-Pettersson C. 2008. Nebulin--a giant chameleon. *Adv Exp Med Biol* 642:28-39.

Ravenscroft G, Miyatake S, Lehtokari VL, Todd EJ, Vornanen P, Yau KS, Hayashi YK, Miyake N, Tsurusaki Y, Doi H, Saitsu H, Osaka H et al. 2013. Mutations in KLHL40 are a frequent cause of severe autosomal-recessive nemaline myopathy. *Am J Hum Genet* 93:6-18.

Romero NB, Lehtokari VL, Quijano-Roy S, Monnier N, Claeys KG, Carlier RY, Pellegrini N, Orlikowski D, Barois A, Laing NG, Lunardi J, Fardeau M et al. 2009. Core-rod myopathy caused by mutations in the nebulin gene. *Neurology* 73:1159-1161.

Sambuughin N, Yau KS, Olive M, Duff RM, Bayarsaikhan M, Lu S, Gonzalez-Mera L, Sivarorai P, Nowak KJ, Ravenscroft G, Mastaglia FL, North KN et al. 2010. Dominant mutations in KBTBD13, a member of the BTB/Kelch family, cause nemaline myopathy with cores. *Am J Hum Genet* 87:842-847.

Scoto M, Cullup T, Cirak S, Yau S, Manzur AY, Feng L, Jacques TS, Anderson G, Abbs S, Sewry C, Jungbluth H, Muntoni F. 2013. Nebulin (NEB) mutations in a childhood onset distal myopathy with rods and cores uncovered by next generation sequencing. *Eur J Hum Genet* 21:1249-1252.

Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornreich R. 2010. Experience with carrier screening and prenatal diagnosis for 16 ashkenazi jewish genetic diseases. *Hum Mutat* 31:1240-1250.

Sewry CA, Brown SC, Pelin K, Jungbluth H, Wallgren-Pettersson C, Labeit S, Manzur A, Muntoni F. 2001. Abnormalities in the expression of nebulin in chromosome-2 linked nemaline myopathy. *Neuromuscul Disord* 11:146-153.

Shenkman Z, Sheffer O, Erez I, Litmanovitch I, Jedeikin R. 2000. Spinal anesthesia for gastrostomy in an infant with nemaline myopathy. *Anesth Analg* 91:858-859.

Shy GM, Engel WK, Somers JE, Wanko T. 1963. Nemaline myopathy. a new congenital myopathy. *Brain* 86:793-810.

Stackhouse R, Chelmow D, Dattel BJ. 1994. Anesthetic complications in a pregnant patient with nemaline myopathy. *Anesth Analg* 79:1195-1197.

Telfer WR, Nelson DD, Waugh T, Brooks SV, Dowling JJ. 2012. Neb: a zebrafish model of nemaline myopathy due to nebulin mutation. *Dis Model Mech* 5:389-396.

Tonino P, Pappas CT, Hudson BD, Labeit S, Gregorio CC, Granzier H. 2010. Reduced myofibrillar connectivity and increased Z-disk width in nebulin-deficient skeletal muscle. *J Cell Sci* 123:384-391.

Wallgren-Pettersson C. 1989. Congenital nemaline myopathy. A clinical follow-up of twelve patients. *J Neurol Sci* 89:1-14.

Wallgren-Pettersson C. 1990. Congenital nemaline myopathy: A longitudinal study. Helsinki: Societas scientiarum Fennica. [N. 200] p.

Wallgren-Pettersson C, Jasani B, Newman GR, Morris GE, Jones S, Singhrao S, Clarke A, Virtanen I, Holmberg C, Rapola J. 1995. Alpha-actinin in nemaline bodies in congenital nemaline myopathy: Immunological confirmation by light and electron microscopy. *Neuromuscul Disord* 5:93-104.

Wallgren-Pettersson C, Laing NG. 2000. Report of the 70th ENMC international workshop: Nemaline myopathy, 11-13 june 1999, naarden, the netherlands. *Neuromuscul Disord* 10:299-306.

Wallgren-Pettersson C, Lehtokari VL, Kalimo H, Paetau A, Nuutinen E, Hackman P, Sewry C, Pelin K, Udd B. 2007. Distal myopathy caused by homozygous missense mutations in the nebulin gene. *Brain* 130:1465-1476.

Witt CC, Burkart C, Labeit D, McNabb M, Wu Y, Granzier H, Labeit S. 2006. Nebulin regulates thin filament length, contractility, and Z-disk structure in vivo. *Embo j* 25:3843-3855.

Yamamoto DL, Vitiello C, Zhang J, Gokhin DS, Castaldi A, Coulis G, Piaser F, Filomena MC, Eggenhuizen PJ, Kunderfranco P, Camerini S, Takano K et al. 2013. The nebulin SH3 domain is dispensable for normal skeletal muscle structure but is required for effective active load bearing in mouse. *J Cell Sci* 126:5477-5489

Yonath H, Reznik-Wolf H, Berkenstadt M, Eisenberg-Barzilai S, Lehtokari VL, Wallgren-Pettersson C, Mehta L, Achiron R, Gilboa Y, Polak-Charcon S, Winder T, Frydman M et al. 2012. Carrier state for the nebulin exon 55 deletion and abnormal prenatal ultrasound findings as potential signs of nemaline myopathy. *Prenat Diagn* 32:70-74.

Figure 1. Different types of variants in *NEB*.

The distribution of 212 different *NEB* variants identified in this study cohort of 159 families.

Figure 2. Clinical entities caused by variants in *NEB*.

The different forms of nemaline myopathy and their incidence in this study cohort of 159 families. Unspecified NM = clinical data was not available. NM-related = families with distal myopathy without nemaline rods, distal forms of NM, core myopathy, distal form of core-rod myopathy, and fetal akinesia/lethal multiple pterygium syndrome.

Table 1. Clinical (severity) classification of NM and other disorders caused by *NEB* mutations (modified from Wallgren-Pettersson et al, 2004)

Form of congenital myopathy	Clinical inclusion (and exclusion) criteria
Severe NM	Onset <u>at or before birth</u> ; no spontaneous movements; no spontaneous respiration, or with severe contractures or fractures at birth
Intermediate NM	<u>Infantile onset</u> ; patient breathing and moving at birth, but unable to maintain respiratory independence, or to sit and walk independently; use of wheelchair before the age of 11 years; contractures developing in early childhood
Typical NM	<u>Onset in infancy</u> ; typical distribution of muscle weakness (weakness most pronounced in facial, bulbar, and respiratory muscles, neck flexors and limb-girdle muscles; initially proximal, later also distal limb involvement); motor milestones delayed but reached; course slowly progressive or non-progressive Exclusion criteria: Contractures/fractures at birth; lack of spontaneous movements and/or respiration at birth; failure to sit/walk independently; use of wheelchair before 11 yrs
Mild childhood or juvenile onset NM	Childhood or juvenile onset

Adult onset NM	Adult onset
Other forms of NM	Unusual associated features such as cardiomyopathy, ophthalmoplegia, CNS involvement or unusual distribution of muscle weakness Exclusion criteria: Distal myopathy caused by nebulin mutations Core-rod myopathy
Distal myopathy	Mainly distal involvement at presentation
Core-rod myopathy	Definite cores and rods on biopsy

Table 2. Families with NM related myopathies (n = 16)

Family ID	Exon/Intron; variant in cDNA; in protein sequence	Additional details
A: Families with distal myopathy without nemaline rods (mild) (n = 4)		
Dist1 (mild)	ex151; c.22249A>C; p.Thr7417Pro ^{E-FAM I}	FIN2
Dist2 (mild)	ex151; c.22249A>C; p.Thr7417Pro ^{E-FAM II}	FIN2
Dist3 (mild)	ex122; c.19097G>T; p.Ser6366Ile ^{E-FAM III}	FIN1
Dist4 (mild)	ex122; c.19097G>T; p.Ser6366Ile ^{E-FAM IV}	FIN1
B: Distal nemaline myopathy (n = 3)		
F156 (mild)	ex122; c.19097G>T; p.Ser6366Ile ^{D-Fam33} int53; c.7228-1G>T; p.?	FIN1
F227 (mild)	ex163; c.23525_23526del; p.Arg7842fs ^{J-Fam1} ex156; c.22993T>C; p.Leu7597Pro ^{J-Fam1}	
F343 (mild)	ex18; c.1622dup; p.Asp542* ^{J-Fam2} int23; c.2211+5G>A; p.? ^{J-Fam2}	
C: Core-rod myopathy with generalized muscle weakness (n = 3)		
F220 (severe)	ex140; c.21006_21007dup; p.Lys7003fs ^G ex171; c.24294_24297dup; p.Glu8100fs ^G	ALT3
F378 (severe)	int122; c.19102-4_19102-10del; p.? ex119; c.18676C>T; p.Gln6226*	Rods in addition to the cores
F400 (mild)	int25; c.2415+1G>A; p.?	Normal strength in lower limbs. Pseudodominant; Father affected, Mother carrier. Rods in addition to the cores
D: Distal form of core-rod myopathy (n = 3)		
CR2 (typical)	del ex55; c.7431+1916_7536+372del; p.Arg2478_Asp2512del ^N ex172; c.24327_24375dup; p.Val8126fs ^N	Ashk. 2.5 kb del ALT3
F282 (typical)	int106; c.16909-2A>G; p.? ^R ex171; c.24294_24297dup; p.Glu8098fs ^R	ALT3
F410 (typical)	ex129; c.19944G>A; p.? ^R	133 kb dup

	dup 5' – ex81; chr2.hg19:g.(152,465,598_152,465,794)_(152,599,010_152,608,650)dup ^R	
E: Families with fetal akinesia/lethal multiple pterygium syndrome (n = 3)		
D12-060 cons	ex29; c.2920C>T; p.Arg974*	
F412	ex120; c.18786 C>G; p.Tyr6262* ex121; c.18981 C>G; p.Tyr6327*	
F384	del ex55; c.7431+1916_7536+372del, p.Arg2478_Asp2512del ^{L-P4} int66; c.9619-2A>G; p.? ^{L-P4}	Ashk. 2.5 kb del

A: Distal myopathy without nemaline rods (n = 4) **B:** Distal nemaline myopathy (n = 3) **C:** Core-rod myopathy with generalized muscle weakness (n = 4) **D:** Distal core myopathy (n = 2) **E:** Families with fetal akinesia/lethal multiple pterygium syndrome (no muscle biopsies taken) (n = 3). Severity is in parentheses. Reference sequence: c.NM_001271208.1 (contains all of the 183 exons including the triplicated region). In Supp Table S1 and Table 2: Cons = consanguineous; HOZ = homozygous mutation, del ex55 = Ashk. = Ashkenazi Jewish Founder mutation; Finnish founder mutations: FIN1 = a missense mutation Ser > Ile in exon 122, FIN2 = a missense mutation Thr > Pro in exon 151, FIN3 = a frameshift mutation in exon 122; ALT1 = mutation in the alternatively spliced exons 63-66 (always expressed together), ALT2 = mutation in the alternatively spliced exons 143 or 144, ALT3 = mutation in the alternatively spliced exons 167-177 (expressed independently), TRI= mutation in the triplicate region.

Published mutations in Supp Table S1 and Table 2: A = Pelin *et al.*, 1999, B = Pelin *et al.*, 2002, C = Anderson *et al.*, 2004, D = Lehtokari *et al.*, 2006, E = Wallgren-Pettersson *et al.*, 2007, F = Lehtokari and Greenleaf *et al.*, 2009, G = Romero and Lehtokari *et al.*, 2009, H = Lawlor *et al.*, 2011, I = Ochala *et al.*, 2011, J = Lehtokari *et al.*, 2011, K = Kapoor *et al.*, 2013, L = Yonath *et al.*, 2012, M = Böhm *et al.*, 2013, N = Scoto *et al.*, 2013, O = Gajda *et al.*, 2013, P = Kiiski *et al.*, 2013, Q = Malfatti *et al.*, 2014, R = Malfatti *et al.* in preparation.

Table 3. *NEB* variants shared by two or more families

Shared variant	Number of families
del ex55 (Ashkenazi founder mutation)	13
ex122; c.19097G>T; p.Ser6366Ile (Finnish mut 1)	10
int32; c.3255+1G>A; p.? (<i>hotspot</i>)	8
int32; c.3255+1G>T; p.? (<i>hotspot</i>)	6
ex151; c.22144A>C; p.Thr7382Pro (Finnish mut 2)	5
ex119; c.18676C>T; p.Gln6226*	4
int4; c.78+1G>A; p.?	3
int13; c.1152+1G>A; p.?	3
int36; c.3987+1G>A; p.?	3
int43; c.5343+5G>A; p.?	3
ex58; c.8031_8041del; p.Lys2677Asnfs*7	3
ex171 ALT; c.24189_24192dup; p.Glu8063Serfs*5	3
ex173 ALT; c.24302_24305dup; p.Leu8102Phefs*18	3
ex175 ALT; c.24527_24528del; p.Pro8176Argfs*4	3
ex18; c.1623del; p.Pro541Profs*16	2
int25; c.2415+1G>A; p.?	2
int29; c.2943+1G>A; p.?	2
ex38; c.4337G>T; p.Gly1446Val	2
int36; c.3987+1_3987+2inv; p.?	2
ex58; c.7964A>G; p.Tyr2655Cys	2
int66; c.9619-2A>G; p.?	2
ex122; c.19048_19057del; p.Thr6350Profs*4 (Finnish mut 3)	2
ex129; c.19944G>A; p.Ser6648	2
ex138; c.20845dup; p.Thr6949Asnfs*16	2
ex158; c.22831C>T; p.Arg7611*	2
ex163; c.23420_23421del; p.Arg7807Serfs*16	2
ex170 ALT; c.24113C>A; p.Ser8038*	2
ex175 ALT; c.24549_24550del; p.Arg8183Serfs*8	2
ex175 ALT; c.24579G>A; p.?	2
ex177 ALT; c.24735_24736del; p.Ala8246*	2
del ex43-45	2
del ex77	2